sr-142806 and Schizophrenia

sr-142806 has been researched along with Schizophrenia* in 1 studies

Reviews

1 review(s) available for sr-142806 and Schizophrenia

Article	Year
Osanetant Sanofi-Synthélabo. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7 Osanetant is a neurokinin (NK3) receptor antagonist under development by Sanofi-Synthélabo (formerly Sanofi) as a potential treatment for schizophrenia [328910]. Sanofi was originally investigating its potential use as a treatment for psychosis and anxiety [169511]. Following phase IIa clinical trials [307656], [328910], [359231], osanetant entered phase IIb development in February 2001 [409432]. Osanetant was the first potent and selective non-peptide antagonist described for the NK3 tachykinin receptor [176305]. It has a higher affinity for human and guinea pig NK3 receptors than for rat NK3 receptors [176305]. In October 1999, Lehman Brothers predicted that the probability of the product reaching the market was 10%, with a possible launch in 2003 and potential peak sales of US $200 million in 2011 [346267]. Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Cardiovascular System; Dopamine; Humans; Piperidines; Receptors, Neurokinin-3; Schizophrenia; Stereoisomerism; Structure-Activity Relationship; Tachykinins	2001

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7

Osanetant is a neurokinin (NK3) receptor antagonist under development by Sanofi-Synthélabo (formerly Sanofi) as a potential treatment for schizophrenia [328910]. Sanofi was originally investigating its potential use as a treatment for psychosis and anxiety [169511]. Following phase IIa clinical trials [307656], [328910], [359231], osanetant entered phase IIb development in February 2001 [409432]. Osanetant was the first potent and selective non-peptide antagonist described for the NK3 tachykinin receptor [176305]. It has a higher affinity for human and guinea pig NK3 receptors than for rat NK3 receptors [176305]. In October 1999, Lehman Brothers predicted that the probability of the product reaching the market was 10%, with a possible launch in 2003 and potential peak sales of US $200 million in 2011 [346267].

Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Cardiovascular System; Dopamine; Humans; Piperidines; Receptors, Neurokinin-3; Schizophrenia; Stereoisomerism; Structure-Activity Relationship; Tachykinins

2001